Drug Trial Radar · NCT03409107
Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)
Last checked: Nov 19, 2026Latest source record: Apr 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
614
Actual
Start
Mar 5, 2018
Primary completion
Oct 7, 2020
Study completion Oct 7, 2020
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this multi-center study in non-dialysis participants with anemia associated with CKD is to evaluate safety, efficacy and quality of life of daprodustat compared to placebo.
Conditions
- Anaemia
Interventions
Daprodustat (GSK1278863)Drug
Daprodustat will be available as 9 millimeter (mm) or 7 mm film-coated tablets. Daprodustat will be administered once daily via oral route and can be taken without regard to food.
PlaceboDrug
Daprodustat matching placebo will be available as 9 mm or 7 mm film coated tablets. Placebo will be administered once daily via oral route and can be taken without regard to food.
Iron therapyDrug
Iron therapy will be administered if ferritin is \<50 Nano gram per milliliter and/or TSAT is \<15 percent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Hemoglobin From Baseline and Over the Evaluation Period (Mean Over Week 24 and 28)Time frame: Baseline (Day 1) and Week 24 to Week 28
Locations
168 sites in 14 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Homewood, Alabama
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Downey, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Lynwood, California
GSK Investigational Site
Northridge, California
GSK Investigational Site
Northridge, California
GSK Investigational Site
Riverside, California
GSK Investigational Site
Salinas, California
GSK Investigational Site
Santa Ana, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Hartford, Connecticut
GSK Investigational Site
Middlebury, Connecticut
GSK Investigational Site
Coral Springs, Florida
GSK Investigational Site
Hollywood, Florida
GSK Investigational Site
Kissimmee, Florida
GSK Investigational Site
Lauderdale Lakes, Florida
GSK Investigational Site
Pembroke Pines, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Adairsville, Georgia
GSK Investigational Site
Macon, Georgia
GSK Investigational Site
Macon, Georgia
GSK Investigational Site
Statesboro, Georgia
GSK Investigational Site
Indianapolis, Indiana
GSK Investigational Site
Overland Park, Kansas
GSK Investigational Site
Buckley, Michigan
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
Saint Clair Shores, Michigan
GSK Investigational Site
Brookhaven, Mississippi
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Rochester, New Hampshire
GSK Investigational Site
Asheville, North Carolina
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Durham, North Carolina
GSK Investigational Site
Midwest City, Oklahoma
GSK Investigational Site
Oklahoma City, Oklahoma
GSK Investigational Site
Beaver, Pennsylvania
GSK Investigational Site
Duncansville, Pennsylvania
GSK Investigational Site
Scottdale, Pennsylvania
GSK Investigational Site
Smithfield, Pennsylvania
Showing 40 of 168 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.